Dr. Reddy's Laboratories Launches Methylprednisolone Sodium Succinate for Injection, USP in the US Market
7 April 2022 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd has launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of Solu-Medrol (methylprednisolone sodium succinate for injection, USP) in the US Market approved by the US Food and Drug Administration (USFDA), the company said.

The Solu-Medrol brand and generic had US sales of approximately USD 144m MAT for the most recent twelve months ending in February 2022 according to IQVIA Health.

Dr. Reddy's Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial,125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.

Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) is an integrated pharmaceutical company, with a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.